Cost of treating chronic hepatitis B: Comparison of current treatment guidelines

Table 2 Participant distribution by disease stage at initial enrolment and management pathways, according to the B positive algorithm and hepatitis B treatment published guidelines n (%)

Treatment guideline	B positive	Modified B positive	EASL, United States experts	APASL	AASLD
HBV DNA level to treat	> 2000 if > 50	> 2000	> 2000	> 2000	> 20 000
	> 20 000 if < 50
ALT (ULN)	> 1.5	> 1.5	> 1	> 2	> 2
Number receiving interferon	61 (4)	81 (6)	108 (8)	54 (4)	33 (2)
Number receiving entecavir	143 (10)	190 (13)	253 (17)	126 (9)	76 (5)
Total on treatment	204 (14)	271 (19)	361 (25)	181 (12)	109 (8)
Total under enhanced surveillance	340 (23)	452 (31)	361 (25)	542 (37)	326 (23)
Total under routine surveillance	907 (63)	728 (50)	728 (50)	728 (50)	1016 (70)
Total	1451 (100)	1451 (100)	1451 (100)	1451 (100)	1451 (100)

Tabulates the estimated number of participants undergoing different monitoring strategies and treatment options, according to recommendations put forward by Australian, Asia-Pacific, United States and European chronic hepatitis B treatment guidelines. ULN: Upper limit of normal; HBV: Hepatitis B virus; EASL: European Associations for the Study of Liver Disease; APASL: Asia-Pacific Associations for the Study of Liver Disease; AASLD: American Associations for the Study of Liver Disease.